When you live with ulcerative colitis, managing daily bowel symptoms, medical appointments, and prescription refills is part of your regular routine. Across the world, millions of people share this journey, yet understanding how widespread the condition is becoming on a global scale is essential for ensuring that healthcare systems provide adequate funding, specialised clinics, and advanced medications for the future.
Now, a 10-year international healthcare forecast reveals that the global footprint of ulcerative colitis is expanding steadily. According to the report, the total number of people diagnosed with ulcerative colitis across seven major world markets will increase from approximately 2.08 million cases in 2025 to more than 2.36 million cases by 2035.
This investigation was a large-scale international forecasting study spanning a 10-year projection window from 2025 to 2035. The research team evaluated national health registries, population census statistics, and patient database records across the 7MM (Seven Major Markets), which represent the major pharmaceutical and healthcare economies of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
To predict these long-term trends, scientists utilised epidemiological forecasting, a high-tech computer modelling method that combines historical population data, disease prevalence rates, and statistical algorithms to project how disease numbers will change over time. The study focused specifically on diagnosed prevalent cases, which measures the total number of people currently living with an officially confirmed, doctor-diagnosed condition, rather than counting only newly diagnosed individuals each year.
By analysing demographic patterns across all seven countries, the research model identified several key drivers shaping the 10-year outlook:
- Steady Annual Growth Rate: Diagnosed prevalent cases of ulcerative colitis are projected to grow at an annual growth rate of over 1.2 per cent across the seven major markets through 2035.
- The United States Holds the Largest Market Share: The United States is forecast to maintain the highest number of total diagnosed cases, driven by a combination of population growth, higher diagnostic screening rates, and environmental factors.
- Impact of Ageing Populations and Better Screening: Increasing life expectancy means that people with ulcerative colitis are living longer, healthier lives, while improved awareness and earlier diagnostic testing mean fewer mild cases go undetected.
- Urbanisation and Lifestyle Factors: Shifting environmental exposures, dietary habits, and modern industrial lifestyles continue to contribute to rising IBD rates globally.
Why This Matters to You as a Patient
If you are managing ulcerative colitis, this global 10-year forecast offers encouraging reassurance and practical benefits for your long-term care:
- This study proves that rising global awareness ensures better access to care: Demonstrating that more than 2.36 million people will be living with ulcerative colitis highlights the growing global importance of IBD, encouraging governments and health services to expand specialist gastroenterology clinics and reduce diagnostic waiting times.
- This study shows that healthcare systems are preparing for long-term support: Knowing that patient numbers are rising ensures that hospital trusts and prescription authorities prioritise secure funding for continuous medical management, nursing support, and non-invasive monitoring tools.
- This study provides evidence that future treatments will become more flexible and personalised: As the global market for ulcerative colitis expands, pharmaceutical companies are accelerating the development of advanced daily oral pills and needle-free biologics.

Leave a Reply